Biotechnology
Company Overview of OncoMed Pharmaceuticals, Inc.
Company Overview
800 Chesapeake Drive
Redwood City, CA 94063
United States
Founded in 2004
85 Employees
Key Executives for OncoMed Pharmaceuticals, Inc.
OncoMed Pharmaceuticals, Inc. Key Developments
OncoMed Pharmaceuticals, Inc. highlighted new data for vantictumab, a monoclonal antibody targeting the Wnt pathway, at a poster session at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL. Vantictumab is a first-in-class antibody that has broad anti-cancer stem cell and anti-tumor activity in patient-derived xenograft tumor models. The presentation at ASCO (Abstract 2540), entitled 'First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the Wnt pathway in a Phase I study for patients with advanced solid tumors,' was the first clinical presentation of this novel agent. Dr. David Smith (University of Michigan Cancer Center at Ann Arbor, MI) presented the data on behalf of the other principal investigators (Dr. Lee Rosen at the University of California, Los Angeles, CA, and Dr. Kyriakos Papadopoulos at The START Center for Cancer Care, San Antonio, TX) and the entire study team. In the ongoing trial of 24 patients, vantictumab was generally well tolerated up to the current dose of 10 mg/kg every three weeks. A bone protection strategy has been successful in ensuring bone health. Pharmacodynamic effects of vantictumab on the Wnt pathway in patient samples have been noted. Three patients with neuroendocrine tumors (NET) experienced prolonged stable disease for 110, 316+, and 385+ days. Based on these data, OncoMed has advanced vantictumab into three Phase 1b trials in specific tumor indications to study its safety in combination with standard-of-care chemotherapy. These trials will initiate in 2013. Vantictumab is part of OncoMed's Wnt pathway collaboration with Bayer HealthCare.
OncoMed Pharmaceuticals, Inc. Presents at Wells Fargo 2013 Healthcare Conference, Jun-19-2013 . Venue: Intercontinental Hotel, Rose Kennedy Ballroom (3rd Floor), 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: John A. Lewicki, Chief Scientific Officer and Executive Vice President, Paul J. Hastings, Chief Executive Officer, President and Director, Shari Annes, IR, William D. Waddill, Chief Financial Officer, Senior Vice President, Treasurer and Assistant Secretary.
OncoMed Pharmaceuticals, Inc. Presents at Jefferies 2013 Global Healthcare Conference, Jun-03-2013 . Venue: Grand Hyatt Hotel, 109 East 42nd Street at Grand Central, New York, New York, United States.
Similar Private Companies By Industry
| Company Name | Region |
| Seredigm Corp. | United States |
| SK Life Science, Inc. | United States |
| Xenos Bioresources, Inc. | United States |
| Reglera, LLC | United States |
| MultiCell Immunotherapeutics, Inc. | United States |
Recent Private Companies Transactions
| Type Date |
Target | |
| No transactions available in the past 12 months. | ||
Most Searched Private Companies
| Company Name | Geographic Region |
| NYC2012, Inc. | United States |
| Bertelsmann AG | Europe |
| Lawyers Committee for Civil Rights Under Law | United States |
| Rush University | United States |
| Greater Houston Partnership | United States |
Post a JobJobs
- Greenfield, IN | CovancePosted: May 31
- Tarrytown, NY | Bridgeview ITPosted: Jun 16
- Illinois | Miller AgPosted: Jun 14
- New Jersey | Marina Sirras & AssociatesPosted: Jun 14
Sponsored Financial Commentaries
Sponsored Links
To contact OncoMed Pharmaceuticals, Inc., please visit www.oncomed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
